is experience with ide-cel car-t in the real-world setting comparable to the karmma trial results?
Published 1 year ago • 135 plays • Length 2:14Download video MP4
Download video MP3
Similar videos
-
7:55
real-world car-t outcomes, use of ide-cel, cilta-cel for myeloma
-
1:28
real-world experience: ide-cel for r/r multiple myeloma
-
13:36
real-world patient cases: car t-cell therapy
-
2:06
subanalysis of the karmma trial: predicting complete response to car-t in multiple myeloma
-
0:50
car-t in multiple myeloma: cilta-cel & ide-cel
-
10:18
ide-cel; bb2121, a bcma-targeted car t-cell therapy, in patients with rrmm: initial karmma results
-
7:49
idecabtagene vicleucel, a bcma-directed car t cell therapy, in rrmm: updated karmma results
-
5:16
updated karmma results: ide-cel in r/r myeloma
-
5:23
karmma-2 cohort 2b update: ide-cel for transplant-ineligible patients with high-risk myeloma
-
9:56
ide-cel vs standard regimens for high-risk multiple myeloma: karmma-3 analysis | asco 2023
-
1:38
real world use of car t-cell therapy in multiple myeloma
-
5:16
idecabtagene vicleucel in pts with relapsed and refractory multiple myeloma: updated karmma results
-
2:35
latest advances in car-t for multiple myeloma: cilta-cel & new car-t platforms
-
7:36
ash23: real world outcomes with ide-cel car-t cell therapy for relapsed myeloma | surbhi sidana, md
-
4:14
challenges with the real-world use of car-t therapy in multiple myeloma
-
4:04
ide-cel versus standard regimens in tce r/r multiple myeloma: updated analysis of karmma-3
-
49:59
car t-cell therapy: multiple myeloma
-
36:37
car t-cell therapy in non-hodgkin lymphoma and multiple myeloma: a clinical update
-
2:41
secondary hrqol domains in the karmma study of ide-cel in myeloma